Individualized antisense oligonucleotide treatment eligibility of patients living with neurodevelopmental diseases. [PDF]
Aartsma-Rus A +9 more
europepmc +1 more source
Prostate Cancer Patient-Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)-Based Personalized Therapy. [PDF]
Tran TT +15 more
europepmc +1 more source
Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism. [PDF]
Wang Y, Chen Y.
europepmc +1 more source
Targeting the lung using siRNA and antisense based oligonucleotides
The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics.
Williams, A.E. +3 more
core
Accurately modeling RNase H-mediated antisense oligonucleotide efficacy. [PDF]
Hill B +9 more
europepmc +1 more source
ApoC-III Antisense Oligonucleotide Therapy Used in Glycogen Storage Disease Type 1a. [PDF]
Burns J, Sutton VR, Zachariah JP.
europepmc +1 more source
Gene-Specific Antisense Oligonucleotide Therapy Targeting AMA1: A Potential Malaria Treatment. [PDF]
Hanifian H +6 more
europepmc +1 more source
Nusinersen: the antisense oligonucleotide at the forefront of spinal muscular atrophy treatment. [PDF]
Singh NN, Ottesen EW, Singh RN.
europepmc +1 more source
Development of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration. [PDF]
Miller WP +26 more
europepmc +1 more source
Biophysics-informed computational framework for predicting antisense oligonucleotide knockdown efficacy under small-data constraints. [PDF]
Guha R, Kim S, Bandaru A, Vivek N.
europepmc +1 more source

